Disc Medicine finalised the pivotal Phase III trial design of bitopertin in erythropoietic protoporphyria (EPP) with the FDA ...

Disc Medicine has finalized the design of the confirmatory trial for its rare blood disorder drug candidate, adding a ...

By Vijay Kumar Malesu Study identifies chlorcyclizine as a potential treatment to reduce protoporphyrin-IX accumulation and ...

Improved methods for the detection of heme and protoporphyrin IX adducts and quantification of heme B from cytochrome P450 containing systems. Validated extended multiplexed LC-MS/MS assay for the ...

[14] 5-ALA has no photosensitivity, but it can produce strong photosensitizer protoporphyrin IX after a series of transformations in cells. Related clinical studies have confirmed that 5-ALA can ...

Detailed price information for Disc Medicine Inc (IRON-Q) from The Globe and Mail including charting and trades.